PA
BOLD

Perceptive Advisors’s Audentes Therapeutics, Inc BOLD Stock Holding History

Perceptive Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-660,406
Closed -$25.2M – 147
2018
Q2 		$25.2M Sell
660,406
-95,809
-13% -$3.55M 0.66% 40
2018
Q1 		$22.7M Sell
756,215
-25,094
-3% -$850K 0.64% 40
2017
Q4 		$24.4M Hold
781,309
– – 0.81% 30
2017
Q3 		$21.9M Buy
781,309
+73,809
+10% +$1.6M 0.84% 28
2017
Q2 		$13.5M Buy
707,500
+700,000
+9,333% +$11.2M 0.68% 40
2017
Q1 		$128K Hold
7,500
– – 0.01% 136
2016
Q4 		$137K Hold
7,500
– – 0.01% 148
2016
Q3 		$134K Buy
+7,500
New +$114K 0.01% 172

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Perceptive Advisors's BOLD Position: Q3 2018 in Review

Perceptive Advisors sold out of Audentes Therapeutics, Inc (BOLD) in Q3 2018, closing a stake of 660,406 shares — an estimated $25.2M sold.

Perceptive Advisors first reported a position in BOLD in Q3 2016 and held it in 8 quarters. The position peaked at $25.2M in Q2 2018. 114 funds tracked by Wall St. Rank hold BOLD as of Q3 2018.

  • Perceptive Advisors reported no remaining Audentes Therapeutics, Inc position as of Q3 2018 after selling out during the quarter.
  • Perceptive Advisors sold 660,406 Audentes Therapeutics, Inc shares in Q3 2018, an estimated $25.2M.
  • Perceptive Advisors first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 8 quarters.
  • Perceptive Advisors's Audentes Therapeutics, Inc position peaked at $25.2M in Q2 2018.
  • 114 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q3 2018.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.